Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

4 Jun 2005

Abstract excerpt

Immunotherapy for the treatment of metastatic melanoma remains a major clinical challenge. The melanoma microenvironment may lead to local T cell tolerance in part through downregulation of costimulatory molecules, such as B7.1 (CD80). We report the results from the first clinical trial, to our knowledge, using a recombinant vaccinia virus expressing B7.1 (rV-B7.1) for monthly intralesional vaccination of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15937544
DOI: 10.1172/jci24624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaPMID 15937544Read ↗

Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic MelanomaSemantic proximity Read ↗

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.Semantic proximity Read ↗

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.Semantic proximity Read ↗

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodySemantic proximity Read ↗

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.Semantic proximity Read ↗

Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Semantic proximity Read ↗

PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection.Semantic proximity Read ↗

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph nodeSemantic proximity Read ↗

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.Semantic proximity Read ↗

A Phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I DataSemantic proximity Read ↗

IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.Semantic proximity Read ↗

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.